Analyst rating coverage is not available for SKYE yet.
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $1.01 current
Highest Target—
Average Target—
Lowest Target—
SKYE analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
2
2
1
1
0
0
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
2
2
1
1
0
0
As of Nov 19, 2026, 0 of 0 active firms rate SKYE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SKYE EPS & revenue forecast
EPS · NEXT QUARTER
$-1.52
Range $-1.52 – $-1.52 · 1 analysts · -41% YoY
Next period, 1 analysts expect Skye Bioscience, Inc. Common Stock to earn $-1.52 a share (range $-1.52 – $-1.52), versus $-2.56 a year earlier. Full-year consensus is $-5.04, growing to $-4.56 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Skye Bioscience, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SKYE.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$32.00+3068.3% to target
Overall win rate
43%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Neutral
$16.00+1484.2% to target
Overall win rate
38%
+ Follow
#3
AG
Ananda Ghosh
HC Wainwright & Co.
Buy
$20.00+1880.2% to target
Coverage
—
+ Follow
#4
AL
Albert Lowe
Craig-Hallum
Neutral
No targeton SKYE
Coverage
—
+ Follow
#5
MD
Michael DiFiore
Evercore ISI
Buy
$10.00+890.1% to target
Coverage
—
+ Follow
SKYE stock forecast FAQ
Who is the most accurate analyst covering SKYE?+
Among analysts who currently cover SKYE, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $32.00 target.
What is Skye Bioscience, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-1.52 per share (range $-1.52 – $-1.52) across 1 analysts. Full-year EPS is projected at $-5.04, rising to $-4.56 the following year.
How much revenue is Skye Bioscience, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading SKYE lately?+
As of Nov 19, 2026, 0 of 0 active firms rate SKYE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SKYE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.